Mereo BioPharma Group PLC ADR (MREO) stock forecast · $48.7M cap
Mereo BioPharma Group PLC ADR (MREO) is a biotechnology company listed on US.
This MREO forecast page states what the cached financials imply — not a price target and not a guarantee. Mereo BioPharma Group PLC ADR outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported MREO revenue for 2026-06-30 was $0. Net income was -$7.0M. Revenue was down 100.0% from 2026-03-31 to 2026-06-30. MREO currently screens at market cap $48.7M.
The near-term path: Revenue was down 100.0% from 2026-03-31 to 2026-06-30. A forecast that ignores that change is just a story.
MREO currently screens at market cap $48.7M. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next MREO 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the MREO stock page.
Not investment advice.